Major Shareholder Share Sale Announcement Released, Chegbai Research Institute Stock Plummets 25%

TechubNews · 2026-03-19T03:59:24+00:00

Cha Vaccine Research Institute's stock price plummeted more than 25%, reaching its lowest level since listing, due to its largest shareholder Cha Biotech divesting shares. This decision has triggered investor concerns about the company's future growth potential. Market experts hold divergent views on both the short-term and long-term impacts of the stock decline, and future operational strategy will be key to recovering the stock price.

TechubNews

2026-03-19 03:59:24

Abstract generation in progress

Cha Vaccine Institute’s stock price plummeted as its largest shareholder, Cha Biotech, decided to sell a large portion of its shares. On the morning of the 19th, the stock price of Cha Vaccine Institute dropped over 25% compared to the previous day, trading at 2,355 won. This is the lowest price since the company went public.

Cha Biotech announced it will sell approximately 8.94 million shares of Cha Vaccine Institute, reducing its stake to 4.99%. Analysts believe this news has worsened investor sentiment. Cha Group explained that the decision was based on the assessment that there is a lack of synergy between the vaccine business and the group’s main growth drivers, which are cell and gene therapies.

The sharp decline in stock price appears to be driven by investor concerns over the company’s future growth potential following Cha Biotech’s share reduction. The market interpreted this large-scale sell-off as a negative signal about the company’s financial health and future strategic direction.

Market experts have offered various opinions on whether this stock decline is a short-term phenomenon or if it will have medium- to long-term impacts on the company’s financial condition. Going forward, the strategic plans and new business initiatives of Cha Vaccine Institute are expected to be key factors in whether the stock price can recover.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.